Melsens Karin, De Keyser Filip, Decuman Saskia, Piette Yves, Vandecasteele Els, Smith Vanessa
Department of Internal Medicine, Faculty of Medicine and Health Sciences, Ghent University, Belgium.
Department of Internal Medicine, Faculty of Medicine and Health Sciences, Ghent University; and Department of Rheumatology, Faculty of Medicine and Health Sciences, Ghent University, Belgium.
Clin Exp Rheumatol. 2016 Sep-Oct;34 Suppl 100(5):186-192. Epub 2016 Jul 6.
Reviewing disease activity indices (DAI) in systemic sclerosis (SSc) and reporting their validation status.
Literature was systematically reviewed on studies documenting the development of DAI, assessing the validation status of DAI and studies using a DAI in their analysis. The qualitative and quantitative validation status of existing DAI was assessed based on OMERACT and on definitions of the American College of Rheumatology (ACR) committee on quality measures.
Three DAI in SSc have been proposed in literature: the European Scleroderma Study Group (EScSG) activity index, the 12-point DAI and the Combined Response Index for Systemic Sclerosis (CRISS). The EScSG activity index is yet applied as an outcome measure in 48 different studies. The EScSG activity index and the CRISS are provisional partially validated DAI.
Future studies are needed to fully validate the EScSG activity index and the CRISS and to assess the validation status of the 12-point DAI.
回顾系统性硬化症（SSc）中的疾病活动指数（DAI）并报告其验证状态。
对记录DAI发展、评估DAI验证状态以及在分析中使用DAI的研究进行系统文献回顾。基于OMERACT和美国风湿病学会（ACR）质量措施委员会的定义，评估现有DAI的定性和定量验证状态。
文献中已提出SSc的三种DAI：欧洲硬皮病研究组（EScSG）活动指数、12分DAI和系统性硬化症综合反应指数（CRISS）。EScSG活动指数已在48项不同研究中用作结局指标。EScSG活动指数和CRISS是临时部分验证的DAI。
需要进一步研究以全面验证EScSG活动指数和CRISS，并评估12分DAI的验证状态。
